<!DOCTYPE html>
<html lang="en" xml:lang="en">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Chapter 2 Liver allocation in Eurotransplant | Organ allocation models in Eurotransplant</title>
  <meta name="description" content="This is the PhD thesis of H.C. de Ferrante" />
  <meta name="generator" content="bookdown 0.42 and GitBook 2.6.7" />

  <meta property="og:title" content="Chapter 2 Liver allocation in Eurotransplant | Organ allocation models in Eurotransplant" />
  <meta property="og:type" content="book" />
  <meta property="og:image" content="/cover/thesis_cover.png" />
  <meta property="og:description" content="This is the PhD thesis of H.C. de Ferrante" />
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Chapter 2 Liver allocation in Eurotransplant | Organ allocation models in Eurotransplant" />
  
  <meta name="twitter:description" content="This is the PhD thesis of H.C. de Ferrante" />
  <meta name="twitter:image" content="/cover/thesis_cover.png" />

<meta name="author" content="Hans Christiaan de Ferrante" />



  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="CHintroduction.html"/>
<link rel="next" href="CHdynremeld.html"/>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.1.0/anchor-sections.css" rel="stylesheet" />
<link href="libs/anchor-sections-1.1.0/anchor-sections-hash.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.1.0/anchor-sections.js"></script>
<script src="libs/kePrint-0.0.1/kePrint.js"></script>
<link href="libs/lightable-0.0.1/lightable.css" rel="stylesheet" />
<link href="libs/bsTable-3.3.7/bootstrapTable.min.css" rel="stylesheet" />
<script src="libs/bsTable-3.3.7/bootstrapTable.js"></script>



<style type="text/css">
  
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
</style>
<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
  margin-bottom: 0em;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Preface</a></li>
<li class="chapter" data-level="" data-path="dankwoord.html"><a href="dankwoord.html"><i class="fa fa-check"></i>Dankwoord</a></li>
<li class="chapter" data-level="1" data-path="CHintroduction.html"><a href="CHintroduction.html"><i class="fa fa-check"></i><b>1</b> Introduction</a>
<ul>
<li class="chapter" data-level="1.1" data-path="CHintroduction.html"><a href="CHintroduction.html#eurotransplant"><i class="fa fa-check"></i><b>1.1</b> Eurotransplant</a></li>
<li class="chapter" data-level="1.2" data-path="CHintroduction.html"><a href="CHintroduction.html#objective-medical-criteria-for-organ-allocation"><i class="fa fa-check"></i><b>1.2</b> Objective medical criteria for organ allocation</a></li>
<li class="chapter" data-level="1.3" data-path="CHintroduction.html"><a href="CHintroduction.html#fairness-in-organ-allocation"><i class="fa fa-check"></i><b>1.3</b> Fairness in organ allocation</a></li>
<li class="chapter" data-level="1.4" data-path="CHintroduction.html"><a href="CHintroduction.html#challenges-in-improving-organ-allocation-systems"><i class="fa fa-check"></i><b>1.4</b> Challenges in improving organ allocation systems</a></li>
<li class="chapter" data-level="1.5" data-path="CHintroduction.html"><a href="CHintroduction.html#outline-of-this-thesis"><i class="fa fa-check"></i><b>1.5</b> Outline of this thesis</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html"><i class="fa fa-check"></i><b>2</b> Liver allocation in Eurotransplant</a>
<ul>
<li class="chapter" data-level="2.1" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#liver-allocation-prior-to-meld"><i class="fa fa-check"></i><b>2.1</b> Liver allocation prior to MELD</a></li>
<li class="chapter" data-level="2.2" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#meld-based-liver-allocation-in-the-united-states"><i class="fa fa-check"></i><b>2.2</b> MELD-based liver allocation in the United States</a></li>
<li class="chapter" data-level="2.3" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#meld-based-liver-allocation-in-eurotransplant"><i class="fa fa-check"></i><b>2.3</b> MELD-based liver allocation in Eurotransplant</a></li>
<li class="chapter" data-level="2.4" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#areas-for-improvement-in-meld-based-allocation-systems"><i class="fa fa-check"></i><b>2.4</b> Areas for improvement in MELD-based allocation systems</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="CHdynremeld.html"><a href="CHdynremeld.html"><i class="fa fa-check"></i><b>3</b> Revising MELD from calendar-time cross-sections with correction for selection bias</a>
<ul>
<li class="chapter" data-level="3.1" data-path="CHdynremeld.html"><a href="CHdynremeld.html#introduction"><i class="fa fa-check"></i><b>3.1</b> Introduction</a></li>
<li class="chapter" data-level="3.2" data-path="CHdynremeld.html"><a href="CHdynremeld.html#materials-and-methods"><i class="fa fa-check"></i><b>3.2</b> Materials and methods</a></li>
<li class="chapter" data-level="3.3" data-path="CHdynremeld.html"><a href="CHdynremeld.html#results"><i class="fa fa-check"></i><b>3.3</b> Results</a></li>
<li class="chapter" data-level="3.4" data-path="CHdynremeld.html"><a href="CHdynremeld.html#discussion"><i class="fa fa-check"></i><b>3.4</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="4" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html"><i class="fa fa-check"></i><b>4</b> Sex disparity in liver allocation within Eurotransplant</a>
<ul>
<li class="chapter" data-level="4.1" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#introduction-1"><i class="fa fa-check"></i><b>4.1</b> Introduction</a></li>
<li class="chapter" data-level="4.2" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#materials-and-methods-1"><i class="fa fa-check"></i><b>4.2</b> Materials and methods</a></li>
<li class="chapter" data-level="4.3" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#results-1"><i class="fa fa-check"></i><b>4.3</b> Results</a></li>
<li class="chapter" data-level="4.4" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#discussion-1"><i class="fa fa-check"></i><b>4.4</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="CHelassimulator.html"><a href="CHelassimulator.html"><i class="fa fa-check"></i><b>5</b> The ELAS simulator</a>
<ul>
<li class="chapter" data-level="5.1" data-path="CHelassimulator.html"><a href="CHelassimulator.html#introduction-2"><i class="fa fa-check"></i><b>5.1</b> Introduction</a></li>
<li class="chapter" data-level="5.2" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elassystem"><i class="fa fa-check"></i><b>5.2</b> The Eurotransplant Liver Allocation System (ELAS)</a></li>
<li class="chapter" data-level="5.3" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasdesign"><i class="fa fa-check"></i><b>5.3</b> The design of the ELAS simulator</a></li>
<li class="chapter" data-level="5.4" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasmodules"><i class="fa fa-check"></i><b>5.4</b> Modules of the ELAS simulator</a></li>
<li class="chapter" data-level="5.5" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasvv"><i class="fa fa-check"></i><b>5.5</b> Verification and validation</a></li>
<li class="chapter" data-level="5.6" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elascasestudies"><i class="fa fa-check"></i><b>5.6</b> Case studies: the impact of modifying ELAS rules</a></li>
<li class="chapter" data-level="5.7" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasconclusion"><i class="fa fa-check"></i><b>5.7</b> Conclusions and discussion</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html"><i class="fa fa-check"></i><b>6</b> Kidney allocation in Eurotransplant</a>
<ul>
<li class="chapter" data-level="6.1" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html#hla-matching-versus-fairness"><i class="fa fa-check"></i><b>6.1</b> HLA matching versus fairness</a></li>
<li class="chapter" data-level="6.2" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html#kidney-allocation-programs-in-eurotransplant"><i class="fa fa-check"></i><b>6.2</b> Kidney allocation programs in Eurotransplant</a></li>
<li class="chapter" data-level="6.3" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html#contemporary-challenges-in-kidney-allocation"><i class="fa fa-check"></i><b>6.3</b> Contemporary challenges in kidney allocation</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="CHvpra.html"><a href="CHvpra.html"><i class="fa fa-check"></i><b>7</b> Access to transplantation for immunized candidates</a>
<ul>
<li class="chapter" data-level="7.1" data-path="CHvpra.html"><a href="CHvpra.html#introduction-3"><i class="fa fa-check"></i><b>7.1</b> Introduction</a></li>
<li class="chapter" data-level="7.2" data-path="CHvpra.html"><a href="CHvpra.html#materials-and-methods-2"><i class="fa fa-check"></i><b>7.2</b> Materials and methods</a></li>
<li class="chapter" data-level="7.3" data-path="CHvpra.html"><a href="CHvpra.html#results-2"><i class="fa fa-check"></i><b>7.3</b> Results</a></li>
<li class="chapter" data-level="7.4" data-path="CHvpra.html"><a href="CHvpra.html#discussion-2"><i class="fa fa-check"></i><b>7.4</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="8" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html"><i class="fa fa-check"></i><b>8</b> The ETKidney simulator</a>
<ul>
<li class="chapter" data-level="8.1" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#introduction-4"><i class="fa fa-check"></i><b>8.1</b> Introduction</a></li>
<li class="chapter" data-level="8.2" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneyalloc"><i class="fa fa-check"></i><b>8.2</b> The kidney allocation programs of Eurotransplant</a></li>
<li class="chapter" data-level="8.3" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneydesign"><i class="fa fa-check"></i><b>8.3</b> Purpose and design of the ETKidney Simulator</a></li>
<li class="chapter" data-level="8.4" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneymodules"><i class="fa fa-check"></i><b>8.4</b> Modules of the ETKidney simulator</a></li>
<li class="chapter" data-level="8.5" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneyvv"><i class="fa fa-check"></i><b>8.5</b> Verification and validation</a></li>
<li class="chapter" data-level="8.6" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneycasestudies"><i class="fa fa-check"></i><b>8.6</b> Case studies</a></li>
<li class="chapter" data-level="8.7" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneydiscussion"><i class="fa fa-check"></i><b>8.7</b> Discussion and conclusion</a></li>
</ul></li>
<li class="chapter" data-level="9" data-path="CHdiscussion.html"><a href="CHdiscussion.html"><i class="fa fa-check"></i><b>9</b> The way forward</a>
<ul>
<li class="chapter" data-level="9.1" data-path="CHdiscussion.html"><a href="CHdiscussion.html#this-thesis-is-a-sharp-look-at-familiar-problems"><i class="fa fa-check"></i><b>9.1</b> This thesis is a sharp look at familiar problems</a></li>
<li class="chapter" data-level="9.2" data-path="CHdiscussion.html"><a href="CHdiscussion.html#we-need-to-look-beyond-survival-models-for-allocation"><i class="fa fa-check"></i><b>9.2</b> We need to look beyond survival models for allocation</a></li>
<li class="chapter" data-level="9.3" data-path="CHdiscussion.html"><a href="CHdiscussion.html#we-should-look-beyond-aggregate-outcomes"><i class="fa fa-check"></i><b>9.3</b> We should look beyond aggregate outcomes</a></li>
<li class="chapter" data-level="9.4" data-path="CHdiscussion.html"><a href="CHdiscussion.html#scientific-evidence-is-rarely-the-bottleneck"><i class="fa fa-check"></i><b>9.4</b> Scientific evidence is rarely the bottleneck</a></li>
<li class="chapter" data-level="9.5" data-path="CHdiscussion.html"><a href="CHdiscussion.html#the-chicken-and-egg-problem-in-allocation-development"><i class="fa fa-check"></i><b>9.5</b> The “chicken-and-egg” problem in allocation development</a></li>
<li class="chapter" data-level="9.6" data-path="CHdiscussion.html"><a href="CHdiscussion.html#we-need-more-constructive-dialogue"><i class="fa fa-check"></i><b>9.6</b> We need more constructive dialogue</a></li>
</ul></li>
<li class="appendix"><span><b>Appendix</b></span></li>
<li class="chapter" data-level="A" data-path="APPipcw.html"><a href="APPipcw.html"><i class="fa fa-check"></i><b>A</b> Inverse Probability Censoring Weights</a>
<ul>
<li class="chapter" data-level="" data-path="APPipcw.html"><a href="APPipcw.html#definition-of-ipcw-weights"><i class="fa fa-check"></i>Definition of IPCW weights</a></li>
</ul></li>
<li class="chapter" data-level="B" data-path="APPimputation.html"><a href="APPimputation.html"><i class="fa fa-check"></i><b>B</b> Completing the status updates streams for transplant recipients</a>
<ul>
<li class="chapter" data-level="B.1" data-path="APPimputation.html"><a href="APPimputation.html#step-1-and-2-construction-of-the-pseudo-observations"><i class="fa fa-check"></i><b>B.1</b> Step 1 and 2: Construction of the pseudo-observations</a></li>
<li class="chapter" data-level="B.2" data-path="APPimputation.html"><a href="APPimputation.html#step-3-fitting-a-model-for-the-mean-restricted-survival-time"><i class="fa fa-check"></i><b>B.2</b> Step 3: Fitting a model for the mean restricted survival time</a></li>
<li class="chapter" data-level="B.3" data-path="APPimputation.html"><a href="APPimputation.html#step-4-constructing-future-statuses"><i class="fa fa-check"></i><b>B.3</b> Step 4: Constructing future statuses</a></li>
<li class="chapter" data-level="B.4" data-path="APPimputation.html"><a href="APPimputation.html#step-4.2-matching-the-patient-to-a-particular-patient-in-the-risk-set"><i class="fa fa-check"></i><b>B.4</b> Step 4.2: matching the patient to a particular patient in the risk set</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="summary.html"><a href="summary.html"><i class="fa fa-check"></i>Summary</a></li>
<li class="chapter" data-level="" data-path="course-of-life.html"><a href="course-of-life.html"><i class="fa fa-check"></i>Course of Life</a></li>
<li class="chapter" data-level="" data-path="list-of-publications.html"><a href="list-of-publications.html"><i class="fa fa-check"></i>List of publications</a></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Organ allocation models in Eurotransplant</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="CHprefaceliver" class="section level1 hasAnchor" number="2">
<h1><span class="header-section-number">Chapter 2</span> Liver allocation in Eurotransplant<a href="CHprefaceliver.html#CHprefaceliver" class="anchor-section" aria-label="Anchor link to header"></a></h1>
<p>Liver transplantation is the only curative therapy for patients with acute liver
failure or end-stage liver disease (ESLD), and is the preferred treatment option for
several other liver conditions. The majority of candidates who wait for a liver
transplant have cirrhosis, a chronic liver condition in which inflammation leads
to scarring of the liver. Cirrhosis can be caused by hepatitis B, hepatitis C,
alcohol abuse, metabolic disorders, or a combination thereof <span class="citation"><a href="#ref-olearyIndicationsLiverTransplantation2008">[21]</a></span>.
By itself, cirrhosis is not an indication for a liver
transplantation. However, cirrhosis may progress to a stage where the patient
develops clinical symptoms, such as ascites, encephalopathy, or variceal bleeding <span class="citation"><a href="#ref-olearyIndicationsLiverTransplantation2008">[21]</a></span>.
With such “decompensating” symptoms, liver transplantation can be indicated.
Eventually, decompensated cirrhosis may progress into multiple organ failure
– a syndrome now recognized as acute-on-chronic liver failure (ACLF),
which is associated with a high short-term mortality risk <span class="citation"><a href="#ref-Arroyo2020">[22]</a></span>.</p>
<p>Cirrhosis is also a risk factor for developing hepatocellular carcinoma (HCC),
the most common form of liver cancer. While most patients with HCC have cirrhosis,
they typically have a well-preserved liver function <span class="citation"><a href="#ref-olearyIndicationsLiverTransplantation2008">[21]</a></span>.
Despite not having progressed to ESLD, these candidates may require a
liver transplantation to prevent tumor progression and to reduce the risk of
tumor recurrence after transplantation. For patients with HCC who meet the internationally
accepted Milan criteria, liver transplantation is internationally recognized as
the most effective surgical therapy <span class="citation"><a href="#ref-Galle2018">[23]</a></span>.</p>
<p>Besides cirrhosis, there are many other conditions that can be an indication
for liver transplantation. One group of patients who urgently require access
to transplantation consists of patients with acute liver failure (ALF).
Acute liver failure is characterized
by an unexpected and abrupt loss of liver function, which can be triggered by
among others acute viral hepatitis, mushroom poisoning, or paracetamol intoxication. Without
transplantation, patients with ALF are expected to die within days <span class="citation"><a href="#ref-stravitzAcuteLiverFailure2019">[24]</a></span>.
Examples of chronic, non-cirrhotic indications are polycystic liver disease and cholestatic
liver disease. Polycystic liver disease is a genetic
disorder that causes cysts to grow in the liver and predominantly affects females.
Although polycystic liver disease is not life-threatening, the condition can
cause debilitating symptoms that may justify liver transplantation.
One type of cholestatic liver disease is primary sclerosing cholangitis (PSC),
which has a higher incidence in males. PSC is characterized by inflammation of the bile ducts
which leads to scarring. If PSC is recurrent, liver transplantation may be indicated
because it is a pre-stage for cholangiocarcinoma and associated with a
reduced quality of life <span class="citation"><a href="#ref-olearyIndicationsLiverTransplantation2008">[21]</a></span>.</p>
<p>This far-from-exhaustive overview of indications for liver transplantation
shows that the liver waiting list consists of heterogeneous groups of patients, who require access to liver transplantation for different reasons. Designing a
liver allocation system that adequately serves these heterogeneous patient
groups is a difficult task. In this chapter, we describe how Eurotransplant
has tried to balance the interests of these patient groups.</p>
<div id="liver-allocation-prior-to-meld" class="section level2 hasAnchor" number="2.1">
<h2><span class="header-section-number">2.1</span> Liver allocation prior to MELD<a href="CHprefaceliver.html#liver-allocation-prior-to-meld" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>In the 1990s, Eurotransplant had limited involvement in the allocation of livers.
In fact, the exchange of livers was mandatory only
for candidates who had a High Urgency
(HU) status <span class="citation"><a href="#ref-HaaseKromwijk1999">[7]</a></span>. Candidates with acute liver failure or other
<em>de novo</em> life-threatening conditions were eligible for this status. If
no such candidates were available for transplantation, the transplantation
center responsible for procurement of the liver could freely select a candidate
from their own waiting list for transplantation (subject to blood group rules) <span class="citation"><a href="#ref-demeesterWhichABOmatchingRule2002">[14]</a></span>. If the procurement center did not have
suitable candidates available, Eurotransplant used a rotation system to
offer the liver to other centers. Contacted centers could again freely select
a candidate from their waiting list for transplantation <span class="citation"><a href="#ref-Jost1997">[25]</a>, <a href="#ref-Chapman1997">[26]</a></span>.
How candidates were prioritized was thus mostly left to the discretion of
the transplant centers.</p>
<p>In July 2000, Eurotransplant introduced a patient-oriented allocation system
for the liver <span class="citation"><a href="#ref-Strassburg2004">[27]</a></span>, as was required under the Dutch and
German transplantation laws that were introduced in the 1990s <span class="citation"><a href="#ref-HaaseKromwijk1999">[7]</a></span>. In this system, candidates for liver
transplantation were categorized into four medical urgency groups: high urgency
(T1), chronic disease with acute decompensation (T2), chronic disease with
complications (T3), or chronic disease without complications (T4). Candidates
with a T1 status received international priority, while elective candidates (T2-T4) were prioritized
using a point system that awarded points for the candidate’s medical urgency (T2-T4), their waiting time, and their location relative to the donor <span class="citation"><a href="#ref-minutesELIACMeeting2002">[28]</a></span>.
Candidates were categorized into a T2, T3, or T4 status based on their Child-Pugh
score, which can be used to assess the prognosis of candidates with cirrhosis <span class="citation"><a href="#ref-Strassburg2004">[27]</a>, <a href="#ref-Jung2008">[29]</a></span>.</p>
<p>The most important disadvantage of this patient-oriented system was that waiting
time had a dominant role <span class="citation"><a href="#ref-Strassburg2004">[27]</a>, <a href="#ref-Jung2008">[29]</a></span>, which incentivized the
transplant centers to refer their candidates early for transplantation. In Eurotransplant,
this contributed to a tenfold increase in the number of candidates who
waited for liver transplantation between 1991 and 2006 <span class="citation"><a href="#ref-Jung2008">[29]</a></span>. As a result,
waiting times in Germany exceeded 200 days even for candidates with a T2 status,
who by definition have acute decompensation <span class="citation"><a href="#ref-Strassburg2004">[27]</a></span>. With
these waiting times, it was observed that the candidates with the shortest
waiting times faced an increased risk of dying <span class="citation"><a href="#ref-minutesELIACMeeting2002">[28]</a></span>. This
indicated that the allocation system failed to adequately rank candidates on
medical urgency.</p>
<p>Classifying medical urgency based on the Child-Pugh score was also contentious
because these scores are partially based on a subjective assessment of the candidate’s
encephalopathy grade and ascites grade <span class="citation"><a href="#ref-Jung2008">[29]</a>, <a href="#ref-wiesnerModelEndstageLiver2003">[30]</a></span>.
Concerns were voiced in the Eurotransplant Liver and Intestine Committee (ELIAC)
that centers abused these subjective criteria, and <em>“tried to push their candidates into
a T2 status”</em> <span class="citation"><a href="#ref-minutesELIACMeeting2006">[31]</a></span>. Moreover, ascites and encephalopathy
are also specifically linked to cirrhosis, such that candidates with
other liver conditions were typically assigned a T4 status <span class="citation"><a href="#ref-Strassburg2004">[27]</a></span>.
Consensus in ELIAC was that this was unfair to candidates with hepatocellular
carcinoma or metabolic disorders <span class="citation"><a href="#ref-minutesELIACMeeting2001">[32]</a></span>.</p>
</div>
<div id="meld-based-liver-allocation-in-the-united-states" class="section level2 hasAnchor" number="2.2">
<h2><span class="header-section-number">2.2</span> MELD-based liver allocation in the United States<a href="CHprefaceliver.html#meld-based-liver-allocation-in-the-united-states" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>In the United States, a similar liver allocation system had been in use since 1998.
This system also prioritized candidates using four medical urgency categories
that were based on the Child-Pugh score. Freeman et al. (2004) reported that
under this system there was <em>“virtually no relation between waiting time and
mortality for each medical urgency status”</em>. This finding – reported on behalf
of UNOS, the organ allocation organization of the United States – motivated a
search for an alternative disease severity score that could be used to prioritize
candidates for liver transplantation. This disease severity score would become
the Model for End-stage Liver Disease (MELD) score, which was implemented in 2002.</p>
<p>Notably, this MELD score was not originally developed to predict survival on the
liver transplantation waiting list. Instead, MELD was developed by Malinchoc et al. (2000)
to predict 90-day survival after an elective transjugular intrahepatic porto-systemic
shunt (TIPS) procedure <span class="citation"><a href="#ref-malinchocModelPredictPoor2000">[33]</a></span>. These procedures are
indicated in cirrhotic patients with acute decompensation to prevent variceal
rebleeding, or to treat refractory ascites. Malinchoc et al. demonstrated that
this model outperformed the Child-Pugh score in predicting 90-day survival after TIPS.
Whether this scoring system could also be used to rank candidates for liver
transplantation was first studied by Kamath et al.,
who showed that MELD could also predict the 90-day mortality of three
other cirrhotic patient groups: hospitalized cirrhotic
patients who did not undergo a TIPS procedure, ambulatory patients with cirrhosis,
and patients with biliary cirrhosis <span class="citation"><a href="#ref-kamathModelPredictSurvival2001">[34]</a></span>.
Furthermore, Kamath et al. showed that
including clinical symptoms or disease etiology only minimally improved the model’s
predictive performance, which meant that survival could be
adequately predicted based on blood-based biomarkers alone. Candidates for
liver transplantation could thereby be prioritized solely based on objective
medical criteria, which was considered advantageous. Subsequent external validations have
demonstrated that MELD is indeed superior to the Child-Pugh score for predicting
90-day survival on the liver waiting list
<span class="citation"><a href="#ref-wiesnerModelEndstageLiver2003">[30]</a></span>.</p>
<p>Based on these findings, a policy to prioritize patients using MELD was approved
in the United States in November 2001. Under this system, which was implemented
in February 2002, MELD scores are calculated based on measurements of
serum bilirubin (mg/dl),
serum creatinine (mg/dl) and the International Normalized Ratio (INR)
of prothrombin time, using the following formula:</p>
<p><span class="math display">\[6.43\  + 3.78\ln\left( \text{bilirubin} \right) + 9.57\ln\left( \text{creatinine} \right) + 11.20\ln\left(\text{INR}\right).\]</span></p>
<p>In calculating MELD scores, the laboratory measurements for biomarkers are set to
a minimum of 1 to prevent negative scores. UNOS also proposed to cap
serum creatinine at 4.0 mg/dl, to limit MELD scores to a maximum of 40, and to
rank candidates by their rounded MELD scores. Because of these choices, MELD
scores range from 6 to 40.</p>
<p>It was anticipated that a purely MELD-based allocation would underserve
candidates with metabolic disease, cholestatic liver disease, or hepatocellular carcinoma
<span class="citation"><a href="#ref-wiesnerModelEndstageLiver2003">[30]</a>, <a href="#ref-kamathModelPredictSurvival2001">[34]</a></span>.
To help such candidates access transplantation, policymakers in the United States
also introduced an elaborate exception point system that awards exception points
for various non-cirrhotic indications.</p>
</div>
<div id="meld-based-liver-allocation-in-eurotransplant" class="section level2 hasAnchor" number="2.3">
<h2><span class="header-section-number">2.3</span> MELD-based liver allocation in Eurotransplant<a href="CHprefaceliver.html#meld-based-liver-allocation-in-eurotransplant" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>In 2003, the ELIAC recommended assessing whether MELD could replace the Child-Pugh
score for liver allocation in Eurotransplant <span class="citation"><a href="#ref-Jung2008">[29]</a></span>. Following this
recommendation, delegates from Eurotransplant visited UNOS in 2003 and 2004 to
study how a MELD-based allocation system could be adapted for Eurotransplant.
These visits ultimately led to the introduction of MELD-based liver allocation in
Eurotransplant in December 2006.
Because of these visits, the core of Eurotransplant’s MELD-based liver allocation
system closely mirrors UNOS’ implementation. For example, both systems give
priority to candidates with acute liver failure and prioritize “elective”
(i.e., non-HU) candidates using MELD scores. In both systems, prioritization is
based on the <em>“match-MELD”</em> score, which is the maximum of the <em>“lab-MELD</em>” score
(calculated from biomarkers) and exception points. Eurotransplant also
uses the exact same formulas as UNOS to calculate the lab-MELD and exception scores.</p>
<p>Within MELD-based liver allocation in Eurotransplant, international sharing is mandatory
only for candidates with a High Urgency (HU) status and those awaiting a combined
transplantation. Otherwise, candidates located in the same country as the donor
have priority in Eurotransplant. A distinctive feature of Eurotransplant’s
liver allocation system is
that an obligation system was introduced, which ensures that livers exported
with international priority are paid back by the importing country <span class="citation"><a href="#ref-jochmansAdultLiverAllocation2017">[35]</a></span>.
Another difference lies in the prioritization of pediatric candidates: within
Eurotransplant, children are prioritized with exception points, while UNOS
uses PELD, a disease severity score developed specifically for children
<span class="citation"><a href="#ref-freemanImprovingLiverAllocation2004">[36]</a></span>.</p>
<p>MELD-based liver allocation in Eurotransplant has to abide by the national regulations
of its member countries, which introduces considerable complexity into the
allocation system. For example, only in Germany and the Netherlands is the ranking
of candidates completely based on the match-MELD. In Austria, Croatia, Hungary
and Slovenia, procurement centers are still allowed to select a candidate from
their own waiting list, as was the case under the center-based allocation system
of the 1990s. In Belgium, a mixture of center- and patient-based allocation
is used, with centers free to select a candidate for Donation after Cardiac Death
(DCD) donors, but not for Donation after Brain Death (DBD) donors <span class="citation"><a href="#ref-jochmansAdultLiverAllocation2017">[35]</a></span>.
National competent authorities have varying opinions regarding which indications deserve
to be prioritized with exception points. To accommodate these different views,
Eurotransplant’s member countries have completely separate exception point systems, with exception
points valid only for national allocation.</p>
</div>
<div id="areas-for-improvement-in-meld-based-allocation-systems" class="section level2 hasAnchor" number="2.4">
<h2><span class="header-section-number">2.4</span> Areas for improvement in MELD-based allocation systems<a href="CHprefaceliver.html#areas-for-improvement-in-meld-based-allocation-systems" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>Since Eurotransplant switched allocation by MELD in December 2006,
several potential areas for improvement for MELD-based liver allocation have been
identified. One known limitation of MELD is that
it underestimates the waiting list mortality risks for certain
cirrhotic patient groups. These include candidates with low serum sodium
levels (hyponatremia) <span class="citation"><a href="#ref-kimHyponatremiaMortalityPatients2008a">[37]</a></span>. This has motivated
UNOS to switch in 2016 to liver allocation based on the MELD-Na score, which adds
serum sodium to the MELD formula. A second patient group consists of female transplantation
candidates, who are more likely to have an adverse waiting list outcome than males
in the United States <span class="citation"><a href="#ref-moylanDisparitiesLiverTransplantation2008">[38]</a></span>. To address
this disparity, UNOS liver allocation has become based on MELD 3.0 in 2023, which
adds serum albumin to the formula and adds 1.33 to the MELD score of female transplant candidates <span class="citation"><a href="#ref-kimMELD3point0">[20]</a></span>. In Chapter <a href="CHsexdisparity.html#CHsexdisparity">4</a>, we examine whether
females are also more likely to face an adverse waiting list outcome in
Eurotransplant, and assess why that would be the case.</p>
<p>A second area of improvement concerns the formula that is used to calculate MELD scores.
The coefficients in this formula were based on a Cox proportional hazards model
that was developed for the prediction of survival after a TIPS procedure, not survival
on the liver waiting list. A rich literature exists which seeks to re-estimate
these coefficients on candidates for liver transplantation <span class="citation"><a href="#ref-merionLongitudinalAssessmentMortality2003">[39]</a>, <a href="#ref-sharmaReweightingModelEndStage2008">[40]</a>, <a href="#ref-leiseRevisedModelEndstage2011">[41]</a></span>.
A related area of criticism concerns the choices that UNOS has made in introducing MELD,
such as capping creatinine at 4.0 mg/dl and
calculating MELD with minimum values of 1 for all biomarkers. Studies have
argued that these choices lacked empirical support and have revised these
upper and lower limits <span class="citation"><a href="#ref-leiseRevisedModelEndstage2011">[41]</a></span>. For Eurotransplant specifically,
Goudsmit et al. proposed ReMELD and ReMELD-Na, which were scores obtained by
revising MELD and MELD-Na with retrospective data from Eurotransplant <span class="citation"><a href="#ref-goudsmitRefittingModelEndstage2020">[42]</a></span>. In a case study in Chapter <a href="CHelassimulator.html#CHelassimulator">5</a>, we assess how implementation
of the ReMELD-Na score would affect waiting list outcomes in Eurotransplant.</p>
<p>The studies that revise MELD based on liver transplant candidate data typically
associate a candidate’s 90-day waiting list survival with their MELD biomarkers
reported at listing. This approach inefficiently uses the data that is available
at Eurotransplant, because most candidates have multiple sets of MELD biomarkers
available as centers are required to regularly recertify the MELD scores of their candidates.
In Chapter <a href="CHdynremeld.html#CHdynremeld">3</a>, we assess how this information
can be used to revise MELD more efficiently.</p>
<p>A third potential area of improvement is that the prioritization of candidates based on a
sickest-first principle may result in transplanting candidates who
have a short life expectancy after transplantation. In Eurotransplant, mixed results exist as to
whether allocation based on MELD leads to worse post-transplant outcomes <span class="citation"><a href="#ref-Nagler2005">[43]</a>, <a href="#ref-Weismller2009">[44]</a></span>.
At least in theory, an allocation based on transplant benefit could help prevent such futile
transplantations. Such a benefits-based allocation system was first proposed in
the United States by Schaubel et al. <span class="citation"><a href="#ref-Schaubel2009">[9]</a></span>, but it was never implemented.
In the United Kingdom, allocation of livers has become
based on the <em>Transplant Benefit Score</em> (TBS) since 2018 <span class="citation"><a href="#ref-Allen2024">[19]</a></span>. TBS has
been contentious because it underserved candidates with HCC <span class="citation"><a href="#ref-Attia2023">[45]</a></span> and
it is thought to have reduced access to transplantation for young liver
transplant candidates <span class="citation"><a href="#ref-Attia2024">[46]</a></span>.</p>
<p>A fourth area of improvement is the exception point system that is used to prioritize
non-cirrhotic candidates for transplantation. In the United States,
studies have reported that candidates eligible for exception points were overprioritized
<span class="citation"><a href="#ref-Massie2011">[47]</a>, <a href="#ref-Goldberg2014">[48]</a></span>, which has led to a substantial deprioritization of
candidates with exception points in OPTN, which is the national system that manages organ
allocation in the United States. For example, UNOS first lowered the number
of points awarded to candidates with HCC in 2003, which was followed by removal
of exception points for those with stage I HCC. In 2005, the priority for candidates with stage II HCC was again
lowered, which was followed by a “Delay and Cap” policy for HCC in 2015
<span class="citation"><a href="#ref-pillaiLiverAllocationPolicies2019">[49]</a></span>. With this policy, candidates
with HCC would not be eligible for exception points until they had waited six months
for a liver transplant (the “delay”), and would receive a maximum exception score of 34 points
on the MELD scale (the “cap”). In 2019, UNOS completely removed the 90-day upgrades for all exception points,
a decision motivated by findings that these 90-day upgrades were linked to an increase in the
median MELD score at transplantation of 22 in 2005 to 27 in 2012 <span class="citation"><a href="#ref-northupExcessMortalityLiver2015">[50]</a></span>. To counter such “MELD inflation”, candidates
with exceptions are now awarded a fixed number of points in the United States,
which is specified relative to the median MELD at transplantation (MMAT) <span class="citation"><a href="#ref-Bonner2018">[51]</a></span>. For HCC, this number is
set to the MMAT minus three points.</p>
<p>In Eurotransplant, in contrast, changes to the exception point system have been adopted only sporadically. For example, only in the Netherlands was a six-month waiting period
adopted for HCC, analogous to UNOS’s 2015 “Delay and Cap” policy.
This lack of policy reform is surprising because several articles
have suggested that candidates with exception points are also overprioritized in Eurotransplant
<span class="citation"><a href="#ref-Goet2017">[52]</a>, <a href="#ref-Metselaar2017">[53]</a></span>. Notable in this regard is a study by Umgelter et al. <span class="citation"><a href="#ref-umgelterDisparitiesEurotransplantLiver2017a">[54]</a></span>,
who concluded on behalf of ELIAC that patients with exception points appear to be
advantaged compared to candidates without exception points. In Chapter
<a href="CHelassimulator.html#CHelassimulator">5</a>, we examine how
changes to the exception point system would affect waiting list outcomes in
Belgium, the country in which most exceptions are awarded within Eurotransplant.</p>
<p>As this chapter sets out, the literature is rich with ideas on how MELD-based
liver allocation can be improved. A major barrier to implementing these ideas is
that Eurotransplant has lacked the tools to quantitatively assess how a change
in allocation rules would impact the
liver waiting list outcomes. To fill this gap,
we developed a discrete-event simulator that mimics the liver allocation system in Eurotransplant.
We describe this simulator in detail in Chapter <a href="CHelassimulator.html#CHelassimulator">5</a>.</p>

</div>
</div>
<h3>References</h3>
<div id="refs" class="references csl-bib-body" entry-spacing="0">
<div id="ref-HaaseKromwijk1999" class="csl-entry">
<div class="csl-left-margin">[7] </div><div class="csl-right-inline">B. J. J. M. Haase-Kromwijk, J. de Meester, and G. G. Persijn, <span>“<span>Eurotransplant Foundation</span>: The original framework of organ exchange,”</span> <em>Best Practice &amp; Research Clinical Anaesthesiology</em>, vol. 13, no. 2, pp. 169–178, 1999, doi: <a href="https://doi.org/10.1053/bean.1999.0018">10.1053/bean.1999.0018</a>.</div>
</div>
<div id="ref-Schaubel2009" class="csl-entry">
<div class="csl-left-margin">[9] </div><div class="csl-right-inline">D. E. Schaubel <em>et al.</em>, <span>“Survival benefit-based deceased-donor liver allocation,”</span> <em>American Journal of Transplantation</em>, vol. 9, no. 4, pp. 970–981, 2009, doi: <a href="https://doi.org/10.1111/j.1600-6143.2009.02571.x">10.1111/j.1600-6143.2009.02571.x</a>.</div>
</div>
<div id="ref-demeesterWhichABOmatchingRule2002" class="csl-entry">
<div class="csl-left-margin">[14] </div><div class="csl-right-inline">J. de Meester <em>et al.</em>, <span>“Which <span class="nocase">ABO-matching</span> rule should be the decisive factor in the choice between a highly urgent and an elective patient?”</span> <em>Transplant International</em>, vol. 15, no. 8, pp. 431–435, 2002, doi: <a href="https://doi.org/10.1007/s00147-002-0424-y">10.1007/s00147-002-0424-y</a>.</div>
</div>
<div id="ref-Allen2024" class="csl-entry">
<div class="csl-left-margin">[19] </div><div class="csl-right-inline">E. Allen, R. Taylor, A. Gimson, and D. Thorburn, <span>“Transplant benefit-based offering of deceased donor livers in the <span>United Kingdom</span>,”</span> <em>Journal of Hepatology</em>, vol. 81, no. 3, pp. 471–478, 2024, doi: <a href="https://doi.org/10.1016/j.jhep.2024.03.020">10.1016/j.jhep.2024.03.020</a>.</div>
</div>
<div id="ref-kimMELD3point0" class="csl-entry">
<div class="csl-left-margin">[20] </div><div class="csl-right-inline">W. R. Kim <em>et al.</em>, <span>“<span>MELD</span> 3.0: The <span class="nocase">Model for End-Stage Liver Disease</span> updated for the modern era,”</span> <em>Gastroenterology</em>, vol. 161, no. 6, pp. 1887–1895.e4, 2021, doi: <a href="https://doi.org/10.1053/j.gastro.2021.08.050">10.1053/j.gastro.2021.08.050</a>.</div>
</div>
<div id="ref-olearyIndicationsLiverTransplantation2008" class="csl-entry">
<div class="csl-left-margin">[21] </div><div class="csl-right-inline">J. G. O’Leary, R. Lepe, and G. L. Davis, <span>“Indications for liver transplantation,”</span> <em>Gastroenterology</em>, vol. 134, no. 6, pp. 1764–1776, 2008, doi: <a href="https://doi.org/10.1053/j.gastro.2008.02.028">10.1053/j.gastro.2008.02.028</a>.</div>
</div>
<div id="ref-Arroyo2020" class="csl-entry">
<div class="csl-left-margin">[22] </div><div class="csl-right-inline">V. Arroyo, R. Moreau, and R. Jalan, <span>“Acute-on-chronic liver failure,”</span> <em>New England Journal of Medicine</em>, vol. 382, no. 22, pp. 2137–2145, 2020, doi: <a href="https://doi.org/10.1056/nejmra1914900">10.1056/nejmra1914900</a>.</div>
</div>
<div id="ref-Galle2018" class="csl-entry">
<div class="csl-left-margin">[23] </div><div class="csl-right-inline">P. R. Galle <em>et al.</em>, <span>“<span>EASL</span> clinical practice guidelines: Management of hepatocellular carcinoma,”</span> <em>Journal of Hepatology</em>, vol. 69, no. 1, pp. 182–236, 2018, doi: <a href="https://doi.org/10.1016/j.jhep.2018.03.019">10.1016/j.jhep.2018.03.019</a>.</div>
</div>
<div id="ref-stravitzAcuteLiverFailure2019" class="csl-entry">
<div class="csl-left-margin">[24] </div><div class="csl-right-inline">R. T. Stravitz and W. M. Lee, <span>“Acute liver failure,”</span> <em>The Lancet</em>, vol. 394, no. 10201, pp. 869–881, 2019, doi: <a href="https://doi.org/10.1016/S0140-6736(19)31894-X">10.1016/S0140-6736(19)31894-X</a>.</div>
</div>
<div id="ref-Jost1997" class="csl-entry">
<div class="csl-left-margin">[25] </div><div class="csl-right-inline">U. Jost and B. Ringe, <span>“Principles of <span>Liver</span> <span>Allocation</span> in <span>Eurotransplant</span>,”</span> in <em>Procurement, <span>Preservation</span> and <span>Allocation</span> of <span>Vascularized</span> <span>Organs</span></em>, Springer Netherlands, 1997, ch. 23, pp. 201–207. doi: <a href="https://doi.org/10.1007/978-94-011-5422-2_23">10.1007/978-94-011-5422-2_23</a>.</div>
</div>
<div id="ref-Chapman1997" class="csl-entry">
<div class="csl-left-margin">[26] </div><div class="csl-right-inline">J. de Meester, B. J. J. M. Haase-Kromwijk, G. G. Persijn, and B. Cohen, <span>“Organization and <span>Logistics</span> in <span>Organ</span> <span>Exchange</span>,”</span> in <em>Organ and <span>Tissue</span> <span>Donation</span> for <span>Transplantation</span></em>, London: Hodder Headline Group, 1997, ch. 12, pp. 226–238.</div>
</div>
<div id="ref-Strassburg2004" class="csl-entry">
<div class="csl-left-margin">[27] </div><div class="csl-right-inline">C. P. Strassburg, T. Becker, J. Klempnauer, and M. P. Manns, <span>“<span>Lebertransplantation</span> zwischen <span>Indikation</span> und <span>Spenderallokation</span>,”</span> <em>Der Internist</em>, vol. 45, no. 11, pp. 1233–1245, 2004, doi: <a href="https://doi.org/10.1007/s00108-004-1295-3">10.1007/s00108-004-1295-3</a>.</div>
</div>
<div id="ref-minutesELIACMeeting2002" class="csl-entry">
<div class="csl-left-margin">[28] </div><div class="csl-right-inline">Eurotransplant, <span>“Minutes of the <span>March</span> 2002 <span>ELIAC</span> <span>Meeting</span>,”</span> Internal document, 2002.</div>
</div>
<div id="ref-Jung2008" class="csl-entry">
<div class="csl-left-margin">[29] </div><div class="csl-right-inline">G. E. Jung, J. Encke, J. Schmidt, and A. Rahmel, <span>“<span class="nocase">Model for End-Stage Liver Disease</span>: Neue <span>Grundlage</span> der <span>Allokation</span> für die <span>Lebertransplantation</span>,”</span> <em>Der Chirurg</em>, vol. 79, no. 2, pp. 157–163, 2008, doi: <a href="https://doi.org/10.1007/s00104-008-1463-4">10.1007/s00104-008-1463-4</a>.</div>
</div>
<div id="ref-wiesnerModelEndstageLiver2003" class="csl-entry">
<div class="csl-left-margin">[30] </div><div class="csl-right-inline">R. Wiesner <em>et al.</em>, <span>“<span class="nocase">Model for End-Stage Liver Disease</span> <span>(MELD)</span> and allocation of donor livers,”</span> <em>Gastroenterology</em>, vol. 124, no. 1, pp. 91–96, 2003, doi: <a href="https://doi.org/10.1053/gast.2003.50016">10.1053/gast.2003.50016</a>.</div>
</div>
<div id="ref-minutesELIACMeeting2006" class="csl-entry">
<div class="csl-left-margin">[31] </div><div class="csl-right-inline">Eurotransplant, <span>“Minutes of the <span>January</span> 2006 <span>ELIAC</span> <span>Meeting</span>,”</span> Internal document, 2006.</div>
</div>
<div id="ref-minutesELIACMeeting2001" class="csl-entry">
<div class="csl-left-margin">[32] </div><div class="csl-right-inline">Eurotransplant, <span>“Minutes of the <span>September</span> 2001 <span>ELIAC</span> <span>Meeting</span>,”</span> Internal document, 2001.</div>
</div>
<div id="ref-malinchocModelPredictPoor2000" class="csl-entry">
<div class="csl-left-margin">[33] </div><div class="csl-right-inline">M. Malinchoc, P. S. Kamath, F. D. Gordon, C. J. Peine, J. Rank, and P. C. J. ter Borg, <span>“A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts,”</span> <em>Hepatology</em>, vol. 31, no. 4, pp. 864–871, 2000, doi: <a href="https://doi.org/10.1053/he.2000.5852">10.1053/he.2000.5852</a>.</div>
</div>
<div id="ref-kamathModelPredictSurvival2001" class="csl-entry">
<div class="csl-left-margin">[34] </div><div class="csl-right-inline">P. S. Kamath <em>et al.</em>, <span>“A model to predict survival in patients with end-stage liver disease,”</span> <em>Hepatology</em>, vol. 33, no. 2, pp. 464–470, 2001, doi: <a href="https://doi.org/10.1053/jhep.2001.22172">10.1053/jhep.2001.22172</a>.</div>
</div>
<div id="ref-jochmansAdultLiverAllocation2017" class="csl-entry">
<div class="csl-left-margin">[35] </div><div class="csl-right-inline">I. Jochmans, M. van Rosmalen, J. Pirenne, and U. Samuel, <span>“Adult liver allocation in <span>Eurotransplant</span>,”</span> <em>Transplantation</em>, vol. 101, no. 7, pp. 1542–1550, 2017, doi: <a href="https://doi.org/10.1097/TP.0000000000001631">10.1097/TP.0000000000001631</a>.</div>
</div>
<div id="ref-freemanImprovingLiverAllocation2004" class="csl-entry">
<div class="csl-left-margin">[36] </div><div class="csl-right-inline">R. B. Freeman, R. H. Wiesner, J. P. Roberts, S. McDiarmid, D. M. Dykstra, and R. M. Merion, <span>“Improving liver allocation: <span>MELD</span> and <span>PELD</span>,”</span> <em>American Journal of Transplantation</em>, vol. 4, pp. 114–131, 2004, doi: <a href="https://doi.org/10.1111/j.1600-6135.2004.00403.x">10.1111/j.1600-6135.2004.00403.x</a>.</div>
</div>
<div id="ref-kimHyponatremiaMortalityPatients2008a" class="csl-entry">
<div class="csl-left-margin">[37] </div><div class="csl-right-inline">W. R. Kim <em>et al.</em>, <span>“Hyponatremia and mortality among patients on the liver-transplant waiting list,”</span> <em>The New England Journal of Medicine</em>, vol. 359, no. 10, pp. 1018–1026, 2008, doi: <a href="https://doi.org/10.1056/NEJMoa0801209">10.1056/NEJMoa0801209</a>.</div>
</div>
<div id="ref-moylanDisparitiesLiverTransplantation2008" class="csl-entry">
<div class="csl-left-margin">[38] </div><div class="csl-right-inline">C. A. Moylan, C. W. Brady, J. L. Johnson, A. D. Smith, J. E. Tuttle-Newhall, and A. J. Muir, <span>“Disparities in liver transplantation before and after introduction of the <span>MELD</span> score,”</span> <em>JAMA</em>, vol. 300, no. 20, pp. 2371–2378, 2008, doi: <a href="https://doi.org/10.1001/jama.2008.720">10.1001/jama.2008.720</a>.</div>
</div>
<div id="ref-merionLongitudinalAssessmentMortality2003" class="csl-entry">
<div class="csl-left-margin">[39] </div><div class="csl-right-inline">R. Merion, <span>“Longitudinal assessment of mortality risk among candidates for liver transplantation,”</span> <em>Liver Transplantation</em>, vol. 9, no. 1, pp. 12–18, 2003, doi: <a href="https://doi.org/10.1053/jlts.2003.50009">10.1053/jlts.2003.50009</a>.</div>
</div>
<div id="ref-sharmaReweightingModelEndStage2008" class="csl-entry">
<div class="csl-left-margin">[40] </div><div class="csl-right-inline">P. Sharma, D. E. Schaubel, C. S. Sima, R. M. Merion, and A. S. F. Lok, <span>“Re-weighting the <span class="nocase">Model for End-Stage Liver Disease</span> score components,”</span> <em>Gastroenterology</em>, vol. 135, no. 5, pp. 1575–1581, 2008, doi: <a href="https://doi.org/10.1053/j.gastro.2008.08.004">10.1053/j.gastro.2008.08.004</a>.</div>
</div>
<div id="ref-leiseRevisedModelEndstage2011" class="csl-entry">
<div class="csl-left-margin">[41] </div><div class="csl-right-inline">M. D. Leise, W. R. Kim, W. K. Kremers, J. J. Larson, J. T. Benson, and T. M. Therneau, <span>“A revised <span class="nocase">Model for End-Stage Liver Disease</span> optimizes prediction of mortality among patients awaiting liver transplantation,”</span> <em>Gastroenterology</em>, vol. 140, no. 7, pp. 1952–1960, 2011, doi: <a href="https://doi.org/10.1053/j.gastro.2011.02.017">10.1053/j.gastro.2011.02.017</a>.</div>
</div>
<div id="ref-goudsmitRefittingModelEndstage2020" class="csl-entry">
<div class="csl-left-margin">[42] </div><div class="csl-right-inline">B. F. J. Goudsmit <em>et al.</em>, <span>“Refitting the <span class="nocase">Model for End-Stage Liver Disease</span> for the <span>Eurotransplant</span> region,”</span> <em>Hepatology</em>, 2020, doi: <a href="https://doi.org/10.1002/hep.31677">10.1002/hep.31677</a>.</div>
</div>
<div id="ref-Nagler2005" class="csl-entry">
<div class="csl-left-margin">[43] </div><div class="csl-right-inline">E. Nagler, H. Van Vlierberghe, I. Colle, R. Troisi, and B. de Hemptinne, <span>“Impact of <span>MELD</span> on short-term and long-term outcome following liver transplantation: A <span>European</span> perspective,”</span> <em>European Journal of Gastroenterology &amp; Hepatology</em>, vol. 17, no. 8, pp. 849–856, 2005, doi: <a href="https://doi.org/10.1097/00042737-200508000-00012">10.1097/00042737-200508000-00012</a>.</div>
</div>
<div id="ref-Weismller2009" class="csl-entry">
<div class="csl-left-margin">[44] </div><div class="csl-right-inline">T. J. Weismüller <em>et al.</em>, <span>“The introduction of <span class="nocase">MELD-based</span> organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics,”</span> <em>Transplant International</em>, vol. 22, no. 10, pp. 970–978, 2009, doi: <a href="https://doi.org/10.1111/j.1432-2277.2009.00915.x">10.1111/j.1432-2277.2009.00915.x</a>.</div>
</div>
<div id="ref-Attia2023" class="csl-entry">
<div class="csl-left-margin">[45] </div><div class="csl-right-inline">A. Attia, I. A. Rowe, E. M. Harrison, T. Gordon-Walker, and B. M. Stutchfield, <span>“Implausible algorithm output in <span>UK</span> liver transplantation allocation scheme: Importance of transparency,”</span> <em>The Lancet</em>, vol. 401, no. 10380, pp. 911–912, 2023, doi: <a href="https://doi.org/10.1016/s0140-6736(23)00114-9">10.1016/s0140-6736(23)00114-9</a>.</div>
</div>
<div id="ref-Attia2024" class="csl-entry">
<div class="csl-left-margin">[46] </div><div class="csl-right-inline">A. Attia <em>et al.</em>, <span>“Effect of recipient age on prioritisation for liver transplantation in the <span>UK:</span> A population-based modelling study,”</span> <em>The Lancet Healthy Longevity</em>, vol. 5, no. 5, pp. e346–e355, 2024, doi: <a href="https://doi.org/10.1016/s2666-7568(24)00044-8">10.1016/s2666-7568(24)00044-8</a>.</div>
</div>
<div id="ref-Massie2011" class="csl-entry">
<div class="csl-left-margin">[47] </div><div class="csl-right-inline">A. B. Massie <em>et al.</em>, <span>“<span>MELD</span> exceptions and rates of waiting list outcomes,”</span> <em>American Journal of Transplantation</em>, vol. 11, no. 11, pp. 2362–2371, 2011, doi: <a href="https://doi.org/10.1111/j.1600-6143.2011.03735.x">10.1111/j.1600-6143.2011.03735.x</a>.</div>
</div>
<div id="ref-Goldberg2014" class="csl-entry">
<div class="csl-left-margin">[48] </div><div class="csl-right-inline">D. S. Goldberg, K. Krok, S. Batra, J. F. Trotter, S. M. Kawut, and M. B. Fallon, <span>“Impact of the hepatopulmonary syndrome <span>MELD</span> exception policy on outcomes of patients after liver transplantation: An analysis of the <span>UNOS</span> database,”</span> <em>Gastroenterology</em>, vol. 146, no. 5, pp. 1256–1265.e1, 2014, doi: <a href="https://doi.org/10.1053/j.gastro.2014.01.005">10.1053/j.gastro.2014.01.005</a>.</div>
</div>
<div id="ref-pillaiLiverAllocationPolicies2019" class="csl-entry">
<div class="csl-left-margin">[49] </div><div class="csl-right-inline">A. Pillai, T. Couri, and M. Charlton, <span>“Liver allocation policies in the <span>USA:</span> Past, present, and the future,”</span> <em>Digestive Diseases and Sciences</em>, vol. 64, no. 4, pp. 985–992, 2019, doi: <a href="https://doi.org/10.1007/s10620-019-05549-y">10.1007/s10620-019-05549-y</a>.</div>
</div>
<div id="ref-northupExcessMortalityLiver2015" class="csl-entry">
<div class="csl-left-margin">[50] </div><div class="csl-right-inline">P. G. Northup, N. M. Intagliata, N. L. Shah, S. J. Pelletier, C. L. Berg, and C. K. Argo, <span>“Excess mortality on the liver transplant waiting list: Unintended policy consequences and <span class="nocase">Model for End-Stage Liver Disease</span> <span>(MELD)</span> inflation,”</span> <em>Hepatology</em>, vol. 61, no. 1, pp. 285–291, 2015, doi: <a href="https://doi.org/10.1002/hep.27283">10.1002/hep.27283</a>.</div>
</div>
<div id="ref-Bonner2018" class="csl-entry">
<div class="csl-left-margin">[51] </div><div class="csl-right-inline">K. Bonner, R. Hirose, and J. K. Heimbach, <span>“The evolution of the national liver review board,”</span> <em>Current Transplantation Reports</em>, vol. 5, no. 1, pp. 7–13, 2018, doi: <a href="https://doi.org/10.1007/s40472-018-0176-y">10.1007/s40472-018-0176-y</a>.</div>
</div>
<div id="ref-Goet2017" class="csl-entry">
<div class="csl-left-margin">[52] </div><div class="csl-right-inline">J. C. Goet <em>et al.</em>, <span>“Current policy for allocation of donor livers in the <span>Netherlands</span> advantages primary sclerosing cholangitis patients on the liver transplantation waiting list – a retrospective study,”</span> <em>Transplant International</em>, vol. 31, no. 6, pp. 590–599, 2017, doi: <a href="https://doi.org/10.1111/tri.13097">10.1111/tri.13097</a>.</div>
</div>
<div id="ref-Metselaar2017" class="csl-entry">
<div class="csl-left-margin">[53] </div><div class="csl-right-inline">H. J. Metselaar, A. P. van den Berg, and M. J. Coenraad, <span>“Why we need fairer allocation rules for patients with hepatocellular carcinoma awaiting a liver transplant?”</span> <em>Transplant International</em>, vol. 30, no. 11, pp. 1092–1094, 2017, doi: <a href="https://doi.org/10.1111/tri.12980">10.1111/tri.12980</a>.</div>
</div>
<div id="ref-umgelterDisparitiesEurotransplantLiver2017a" class="csl-entry">
<div class="csl-left-margin">[54] </div><div class="csl-right-inline">A. Umgelter <em>et al.</em>, <span>“Disparities in <span>Eurotransplant</span> liver transplantation wait-list outcome between patients with and without <span class="nocase">Model for End-Stage Liver Disease</span> exceptions,”</span> <em>Liver Transplantation</em>, vol. 23, no. 10, pp. 1256–1265, 2017, doi: <a href="https://doi.org/10.1002/lt.24805">10.1002/lt.24805</a>.</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="CHintroduction.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="CHdynremeld.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": ["thesis.pdf"],
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.9/latest.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
